Navigation Links
UBC professor wins Canada's top pharmaceutical research award
Date:11/19/2012

UBC microbiologist Robert E.W. Hancock has received the Prix Galien 2012 Research Award, widely considered the most prestigious honour in Canadian pharmaceutical research and innovation. Hancock is being recognized for pioneering work unravelling the complex interactions between antibiotics and bacteria.

"The Prix Galien is a testament to Bob Hancock's profound impact on Canadian health research," said Simon Peacock, Dean of UBC's Faculty of Science. "His research focuses on the growing challenge of antibiotic resistance and has resulted in new therapeutic approaches to infectious diseases, like malaria."

Hancock is a leader in Canadian health research, focusing on the prevention and treatment of infectious disease. At UBC he established the Centre for Microbial Diseases and Immunity Research (CMDR) and also co-founded the Centre for Drug Research and Development (CDRD), a national not-for-profit drug development and commercialization centre.

Hancock's research interests include antibiotic uptake and resistance, cationic peptides as novel antimicrobials, innate immunity, and bacterial genomics. His breakthrough discovery of a novel way of selectively modulating immunity and suppressing harmful inflammation while retaining protective immunity has, according to Prix Galien Canada, the potential to revolutionize human healthcare.


'/>"/>

Contact: Silvia Moreno-Garcia
silvia.moreno-garcia@science.ubc.ca
604-822-5001
University of British Columbia
Source:Eurekalert

Page: 1

Related medicine news :

1. Guys, take note: Male birth control pill may be ready soon, says Texas A&M professor
2. IHME professor named first health measurement winner of prestigious innovation award
3. From textbook to flexbook: Professor uses new collaborative tool in the classroom
4. President Obama names SF State math professor a top young scientist
5. Women professorships low in some Scandinavian universities due to sexism
6. Louisiana Tech biomedical engineering professor earns recognition, funding for research
7. Clemson professor awarded nearly $600,000 4-year grant to study language of plants
8. Louisiana Tech University professor earns NSF Early Career Development grant
9. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
10. Environmentally friendly chemistry important for manufacturing pharmaceuticals
11. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , ... January 16, 2017 , ... ... availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol ... protocols to understand the scope of their EHS regulatory obligations and rapidly collect, ...
(Date:1/16/2017)... ... ... well-aware of the following facts at present:, Flu and cold ... effect on keeping this particularly bad strain of the flu away , In ... , These facts are well-known among the team at Woodard! About halfway ...
(Date:1/16/2017)... Hills, CA (PRWEB) , ... January 16, 2017 ... ... a manuscript in the Aesthetic Surgery Journal , the official journal of ... he conducted on lower eyelid retraction surgery. The procedure is designed to correct ...
(Date:1/16/2017)... ... 16, 2017 , ... One thing common to all types of cancer is ... as well. The money spent screening for and treating cancer in the United States ... for cancer more than in any other country that has an advanced healthcare system, ...
(Date:1/16/2017)... ... January 16, 2017 , ... Vixiar Medical, Inc. ... the medical device company, effective immediately. , “This is perfect timing for Kevin ... strong track record in medical device market development and revenue growth, particularly in ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... , January 13, 2017 On ... Jones Industrial Average, and the S&P 500 edged lower ... ended Thursday,s trading session in bearish territories. Taking into ... Services equities this morning: Myriad Genetics Inc. (NASDAQ: ... ), INC Research Holdings Inc. (NASDAQ: INCR ...
(Date:1/13/2017)... NEW YORK , Jan. 12, 2017 /PRNewswire-USNewswire/ ... type 1 diabetes (T1D) research, is pleased to ... advocacy efforts, the Centers for Medicare & Medicaid ... devices approved by the FDA for use in ... a significant step toward making them eligible for ...
(Date:1/13/2017)... YORK , Jan. 12, 2017  Rosen Law ... filing of a class action lawsuit on behalf of ... ALXN ) from February 10, 2014 through November 9, ... recover damages for Alexion investors under the federal securities ... go to http://rosenlegal.com/cases-991.html or call Phillip ...
Breaking Medicine Technology: